Join
Live feed
·
PRReleasevia Quantisnow
Cogent Biosciences Inc. logo

Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) with Priority Review for Bezuclastinib in Combination with Sunitinib for Patients with GIST

ByQuantisnow·Wall Street's wire, on your screen.
COGT· Cogent Biosciences Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track COGT (Cogent Biosciences Inc.) and more on Quantisnow.